Search clinical trials for: BYL719 Breast Cancer

Total 88040 results

Columbia University

Completed

Trial of AEB071 in Combination With BYL719 in Patients With Melanoma

Uveal Melanoma

United States
Peter MacCallum Cancer Centre, Australia
Novartis Pharmaceuticals

Completed

Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer (PIKNIC)

Metastatic Breast Cancer

Australia
Celcuity, Inc.

Recruiting

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) (VIKTORIA-1)

Breast Cancer

Korea, Republic of, United States, Belgium, United Kingdom, Taiwan, France, Italy, Australia, Singapore, Argentina, Canada, India, Mexico, Czechia, Spain, Austria, Bulgaria, Germany, Hungary, Poland, Brazil, Greece, Romania
Stanford University
United States Department of Defense

Recruiting

Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer

Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Novartis Pharmaceuticals

Active, not recruiting

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss (EPIK-B3)

Triple Negative Breast Neoplasms

France, Italy, Croatia, Taiwan, Australia, Argentina, Korea, Republic of, China, Israel, Russian Federation, Slovakia, Slovenia, United Kingdom, Germany, Mexico, Switzerland, Spain, Brazil, Hungary, Malaysia, South Africa, Austria, ... and more
Novartis Pharmaceuticals

Terminated

Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant (TELEPIK)

Advanced Breast Cancer

Sweden
Novartis Pharmaceuticals

Active, not recruiting

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

Advanced Breast Cancer

Japan
Novartis Pharmaceuticals

Completed

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

Estrogen Receptor Positive Breast Cancer | Advanced Solid Tumors With an Alteration of the PIK3CA Gene

United States, Netherlands, Spain, Germany, United Kingdom
Novartis Pharmaceuticals

Completed

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant (BioItaLEE)

Breast Cancer

Italy
Novartis Pharmaceuticals

Available

Managed Access Program to Provide Access to Alpelisib for Patients With Advanced Breast Cancer

HR+, HER2-, Advanced Breast Cancer
Novartis Pharmaceuticals

Terminated

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Advanced or Metastatic ER+ Breast Cancer

United States, France, Germany, Singapore, Italy, Japan, Belgium
Novartis Pharmaceuticals

Completed

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Advanced Solid Tumors | Metastatic Solid Tumors

France, Netherlands, Spain, Canada, Singapore, Germany, Korea, Republic of, Australia, Belgium, Switzerland, Italy, United States
Novartis Pharmaceuticals

Completed

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. (SOLAR-1)

Breast Cancer

United States, France, Spain, United Kingdom, Austria, Germany, Taiwan, Australia, Italy, Israel, Russian Federation, Korea, Republic of, Hong Kong, Thailand, Canada, Hungary, Japan, Lebanon, Belgium, Bulgaria, Greece, Argentina, Peru, Czech... and more
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

Neoplasms | Kidney Neoplasms | Breast Neoplasms | Pancreatic Neuroendocine Neoplasms (pNETs)

France, Germany, United States, Netherlands, Italy, Spain, United Kingdom, Hong Kong, Hungary
MedSIR
Novartis

Recruiting

Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients (METALLICA)

Breast Cancer

Spain
National Cancer Institute (NCI)

Withdrawn

Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic HER2-Negative Breast Carcinoma | Unresectable HER2-Negative Breast Carcinoma
Novartis Pharmaceuticals

Active, not recruiting

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation (EPIK-B2)

Advanced HER2+Breast Cancer

Belgium, France, China, Italy, Spain, Malaysia, United States, Turkey
Novartis Pharmaceuticals

Active, not recruiting

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Breast Cancer

United Kingdom, France, Australia, Korea, Republic of, Spain, Switzerland, Italy, United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Withdrawn

SMMART Adaptive Clinical Treatment (ACT) Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent... and other conditions

United States
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals

Completed

BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer

Metastatic or Locally-advanced Unresectable Breast Cancer

United States
Novartis Pharmaceuticals

Completed

A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer

Neoplasms, Breast Neoplasms, Head and Neck Neoplasms

United States, Spain, France, Italy
Novartis Pharmaceuticals

Completed

Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

Breast Cancer

Canada, Italy, Czechia, United States, Belgium, Austria, Germany, Spain, Japan, Lebanon, Australia, Bulgaria, Israel, Netherlands, Colombia, Hong Kong, Brazil
Lawson Health Research Institute

Active, not recruiting

A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719

Head and Neck Squamous Cell Cancer

Canada
Yonsei University

Unknown

An Open Label, Single Arm, Multicenter Phase II Study of BYL719 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy.

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Korea, Republic of
Novartis Pharmaceuticals

Terminated

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

France, Taiwan, United States, Australia, Canada, Hong Kong, Singapore, Korea, Republic of, Netherlands
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid... and other conditions

United States, Puerto Rico
Novartis Pharmaceuticals

Active, not recruiting

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (BYLieve)

Breast Cancer

United States, Belgium, Italy, Spain, United Kingdom, Taiwan, Canada, Germany, Argentina, Israel, Korea, Republic of, Denmark, France, India, Chile, Netherlands, Singapore, Japan, Mexico
Novartis Pharmaceuticals

Active, not recruiting

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

Breast Neoplasms

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
UNC Lineberger Comprehensive Cancer Center
Novartis Pharmaceuticals

Completed

Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer

Metastatic Breast Cancer

United States
Memorial Sloan Kettering Cancer Center
Novartis

Completed

Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

Breast Cancer

United States
Novartis Pharmaceuticals

Completed

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

Breast Cancer

France, Singapore, Italy, Korea, Republic of, Taiwan, United Kingdom, Spain, United States
Northwestern University
National Cancer Institute (NCI); Novartis

Completed

BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx

HER2-positive Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

United States
Novartis Pharmaceuticals
NantCell, Inc.

Terminated

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

PIK3CA Mutated Advanced Solid Tumors | PIK3CA Amplified Advanced Solid Tumors

Spain, Belgium, United States, Canada
Novartis Pharmaceuticals

Completed

Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma

Relapsed and Refractory Multiple Myeloma

Italy, Germany, Singapore, Australia, United States
Array BioPharma

Completed

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

AML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDS

United States, Australia, Italy, Spain, France, Switzerland, United Kingdom
New Mexico Cancer Care Alliance

No longer available

Compassionate Use of BYL 719 Alpelisib

Lymphangioma

United States
Pfizer

Completed

Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

Colorectal Cancer

United States, Canada, Australia, Germany, Japan, Netherlands, Spain, France, Belgium, Korea, Republic of, Italy, Norway
howard safran
Brown University; Lifespan; Novartis Pharmaceuticals Corporation (Financial supporter)

Terminated

BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study

Rectal Cancer

United States
Novartis Pharmaceuticals

Completed

A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma

China
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals

Completed

Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)

Head and Neck Squamous Cell Cancer

United States
Novartis Pharmaceuticals

Completed

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies

Advanced Solid Tumor

Japan
Novartis Pharmaceuticals

Completed

PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer

Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein

Taiwan, Switzerland, Korea, Republic of, Germany, United States, Japan
Novartis Pharmaceuticals

Available

Managed Access Program (MAP) to Provide Access to Alpelisib (BYL719) for Patients With PIK3CA-Related Overgrowth Spectrum (PROS)

PIK3CA-Related Overgrowth Spectrum (PROS)
Murdoch Childrens Research Institute
Royal Children's Hospital; Peter MacCallum Cancer Centre, Australia

Not yet recruiting

A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations (TARGET-VM)

Arteriovenous Malformations | Vascular Malformations | MAP2K1 Gene Mutation | PIK3CA-related Overgrowth Spectrum | Vascular Anomalies | Lymphangioma | Lymphatic Malformation | KRAS G12D | Venous Malformation | Vascular Anomaly | KRAS G12C | PI3K Gene Mutation | Slow-Flow Vascular Malformation | Fast-Flow Vascular... and other conditions

Australia
University of Arizona
National Cancer Institute (NCI)

Terminated

Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer

HPV Positive Oropharyngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 | CDKN2A-p16 Positive | Stage I Oropharyngeal Squamous Cell Carcinoma AJCC V7 | Stage II Oropharyngeal Squamous Cell Carcinoma...

United States
Seoul National University Hospital
Chungnam National University Hospital; Korean Cancer Study Group

Completed

Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]

Head and Neck Neoplasms | HNSCC

Korea, Republic of
University Health Network, Toronto
Novartis Pharmaceuticals

Completed

Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer

Squamous Cell Carcinoma of Head and Neck | Locoregionally Advanced

Canada
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer

Pancreatic Cancer

United States

Search clinical trials for: BYL719 Breast Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations